Reference of 10386-27-3 , The common heterocyclic compound, 10386-27-3, name is 2-Bromoisonicotinonitrile, molecular formula is C6H3BrN2, its traditional synthetic route has been very mature, but the traditional synthetic route has various shortcomings, such as complicated route, low yield, poor purity, etc., below Introduce a new synthetic route.
To a 25 mL-flask were addedethyl 2-((45)-4-((1-(2-chlorophenyl)-2-(3,3- difluorocyclobutylamino)-2-oxoethyl) (3 -fluoro -phenyl)carbamoyl)-2-oxoimidazolidin- 1- yl)acetate (50 mg, 0.0882 mmol), 2-bromoisonicotinonitrile (21 mg, 0.115 mmol), Cs2CO3 (58 mg,0.176 mmol), Xant-Phos (5.2 mg, 0.OO9mmol), Pd2(dba)3 (8.2 mg, 0.009 mmol) and 1,4- dioxane (1 mL). The mixture was degassed and refilled with nitrogen, and then heated to 100¡ãC for 3hr. The resulting mixture was cooled and filtered and then the filtrate was concentrated in vacuo. The residue was purified by a standard method to give both epimers.?H NMR (400 MFTz, CDC13): 8.63-8.57 (5, 1H), 8.55 ? 8.38 (m, 1H), 7.63 (s, 1H), 7.46 ? 6.84 (m, 8H), 6.45-6.37 (m, 1H), 6.22 ? 5.94 (m,1H), 5.06 ? 4.77 (m, 1H), 4.43-4.37 (m, 1H), 4.32-4.20 (m, 1H), 4.21 (q, J = 7.1 Hz, 2H), 3.82 ? 3.46 (m, 3H), 3.12 ? 2.82 (m, 2H), 2.66 ? 2.25 (m, 2H), 1.29 (t, J = 7.1 Hz, 3H). MS : 669(M+1).
The synthetic route of 10386-27-3 has been constantly updated, and we look forward to future research findings.
Reference:
Patent; AGIOS PHARMACEUTICALS, INC.; LEMIEUX, Rene M.; POPOVICI-MULLER, Janeta; TRAVINS, Jeremy M.; CAI, Zhenwei; CUI, Dawei; ZHOU, Ding; WO2015/10626; (2015); A1;,
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem